Radiopharm Theranostics (RDPTF) Accumulated Expenses (2024 - 2026)

Radiopharm Theranostics (RDPTF) has reported Accumulated Expenses for 3 consecutive years, with $4950.6 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 71.74% year-over-year to $4950.6 in Q2 2026; TTM through Jun 2026 was $4950.6, a 71.74% increase from a year earlier, with the FY2026 full-year figure at $4739.9, up 64.43% from the prior year.
• Accumulated Expenses was $4950.6 for Q2 2026 at Radiopharm Theranostics, up from $2882.6 in the prior quarter.
• Over five years, Accumulated Expenses peaked at $4950.6 in Q2 2026 and troughed at $2634.7 in Q2 2024.
• A 3-year average of $3489.3 and a median of $2882.6 in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses grew 9.41% in 2025 and surged 71.74% in 2026, its largest moves.
• Over 3 years, Accumulated Expenses stood at $2634.7 in 2024, then increased by 9.41% to $2882.6 in 2025, then surged by 71.74% to $4950.6 in 2026.
• The last three Accumulated Expenses figures came in at $4950.6 (Q2 2026), $2882.6 (Q2 2025), and $2634.7 (Q2 2024), per Business Quant data.